SEC Form ARS filed by Zivo Bioscience Inc.
$ZIVO
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2021 | $9.00 | Buy | Maxim Group |
Maxim Group analyst Anthony Vendetti downgrades Zivo Bioscience (OTC:ZIVO) from Buy to Hold.
Gainers Safety Shot (NASDAQ:SHOT) stock increased by 21.5% to $2.77 during Thursday's regular session. Trading volume for Safety Shot's stock is 3.0 million as of 12:30 EST. This is 351.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $103.0 million. Oatly Group (NASDAQ:OTLY) stock moved upwards by 18.61% to $0.63. As of 12:30 EST, Oatly Group's stock is trading at a volume of 5.5 million, which is 143.1% of its average full-day volume over the last 100 days. The company's market cap stands at $373.0 million. Zivo Bioscience (NASDAQ:ZIVO) shares increased by 16.42% to $1.63. As of 12:30 EST, Zivo Bioscience's stock is trading at
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. ZIVO Bioscience The Trade: ZIVO Bioscience, Inc. (NASDAQ:ZIVO) 10% owner Strome Group Inc acquired a total of 366,286 shares
ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO's non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds
ZIVO Bioscience, Inc. (NASDAQ:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company. This new study aims to further validate the efficacy of ZIVO's non-antibiotic, immune-modulating product designed for the prevention and treatment of coccidiosis in broiler chickens. Building upon the positive outcomes of previous trials, this study replicates real-world conditions to ensure the product's effectiveness in commercial poultry production envir
Reduction in intestinal damage enables poultry farms to optimize feed utilization Zivo Bioscience, Inc. (OTCQB:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product's positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO's product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use o
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
3 - Zivo Bioscience, Inc. (0001101026) (Issuer)
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
10-Q - Zivo Bioscience, Inc. (0001101026) (Filer)
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
ZIVOLife to be Granted Exclusive Worldwide Limited License to ZIVO Bioscience Intellectual Property for the Production and Supply of Whole Biomass Algal Products Conference call to be held in early November Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company's corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company's prop
SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00